Patient engagement web platform from Icon bolsters clinical connectivity

Patient-engagement-web-platform-from-Icon-bolsters-clinical-connectivity.jpg
(Image: Getty/ipopba) (Getty Images/iStockphoto)

Icon launches web-based patient engagement platform to provide patients with study-specific information and connectivity.

The drug and device development and commercialization services provider released its web-based patient engagement platform to supplement patient recruitment outreach and visibility.

Icon’s solution will bolster patient recruitment outreach by sites and increased visibility of potential study participants for sponsors and sites. Gretchen Goller, global head of patient recruitment and retention of Icon, told us that the solution is tightly integrated with the company’s internal systems and processes to enable Icon to quickly deliver secure, validated, multi-lingual and engaging websites for its clients.

EB McLindon, senior VP of site and patient solutions, said in a statement that access to patients continues to be a challenge for sponsors and impacts speed to market and overall drug development costs. He added that this solution may increase the predictability and speed of patient recruitment.

According to the company, the service employs a user-friendly interface to guide patients to new and ongoing studies in their specific indication and pre-qualification questionnaire. The solution also enables patients to select the nearest investigative site to match their interest through a geo-targeting site finder application on the platform.

McLindon also told us that clients of Icon will have access to a dashboard to see patient activity on the website and progress on patient engagement.

Icon states that this web-based solution is in an aim to establish connection between the site and the patient. Additionally, the mobile optimized website enables patients to discuss trial participation with caregivers.

Clinical care site staff will be able to see the number of pre-qualification questionnaires in real-time to monitor and report progress to trial sponsors.